JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results
for the quarter ended March 31, 2016.
| Q1 2016 | ||||||
| Revenues | $4.81 billion | |||||
| Cash flow from Operations | $1.38 billion | |||||
| Non-GAAP EPS | $1.20 | |||||
| GAAP EPS | $0.62 | |||||
- Non-GAAP EPS adjusted to exclude December 2015 equity offerings was $1.36, in line with results in the first quarter of 2015.
- Exchange rate fluctuations reduced revenues by $107 million and non-GAAP operating profit by $30 million.
- Second quarter 2016 revenues are expected to be $4.7-$4.9 billion; non-GAAP EPS expected to be $1.16-$1.20; non-GAAP EPS, adjusted to exclude the impact of the December 2015 equity offerings, is expected to be $1.32-$1.36.
- Our guidance for the second quarter of 2016 does not include any Actavis Generics revenues or profit. We expect to close the Actavis Generics acquisition in June 2016.
